Methylergonovine Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Methylergonovine (Methergine) after childbirth and had trouble filling your prescription, you're experiencing something that has affected patients across the country for several years. This guide gives you a clear, honest update on where things stand in 2026 and what you can do about it.

What Is the Current Status of Methylergonovine in 2026?

As of early 2026, the situation is nuanced:

Brand-name Methergine: Permanently discontinued by Novartis. It will not return to market.

Generic Methylergonovine tablets (0.2 mg): Still manufactured by Lupin Pharma, but distribution to retail pharmacies is inconsistent. Many pharmacies simply don't stock it.

Injectable Methylergonovine (0.2 mg/mL): Has appeared on the FDA and ASHP drug shortage lists multiple times. In March 2026, the FDA made a significant ruling: Methergine injection was not withdrawn from market for safety or effectiveness reasons — clearing the path for new generic injectable drug applications (ANDAs). This may improve supply over time.

How Did We Get Here? A Brief Timeline

Decades of brand-name supply: Novartis manufactured Methergine for decades as the standard ergot alkaloid for postpartum hemorrhage management.

Brand discontinuation: Novartis permanently discontinued brand-name Methergine, removing the original product from the market entirely.

Generic entry (2021): Lupin Pharma launched generic Methylergonovine maleate tablets (0.2 mg), providing a new supply source.

Ongoing injectable shortages: The injectable form has appeared on FDA and ASHP drug shortage lists multiple times, with manufacturing and supply chain issues contributing to intermittent availability.

March 2026 — FDA ruling: FDA determined injectable Methergine was not discontinued for safety reasons, enabling new generic injectable manufacturers to seek approval. This is a positive sign for future supply.

Why Does This Feel Like a Shortage Even When It Isn't 'Official'?

Several structural factors make Methylergonovine practically difficult to find, even when there isn't always a formal FDA shortage designation on the oral tablets:

Thin manufacturing base: Only a handful of generic manufacturers produce this drug.

Low demand per pharmacy: Methylergonovine is used almost exclusively in the postpartum period, so most retail pharmacies don't stock it regularly.

Inconsistent distribution: Even when available through wholesalers, distribution to individual pharmacies is uneven across the country.

How Much Does Methylergonovine Cost in 2026?

Cost is another major barrier for patients. The retail cash price for 6 tablets of Methylergonovine 0.2 mg can be up to $375 without any discount — an eye-watering price for a short-course postpartum medication. However, you don't have to pay anywhere near that.

GoodRx: As low as $32.32 for 6 tablets (0.2 mg)

SingleCare: Around $34.82 for 6 tablets

Medicare: Generally not covered by Medicare Part D. Check your specific plan.

For a complete breakdown of savings options, read our guide: How to save money on Methylergonovine in 2026.

What Should You Do If Your Pharmacy Doesn't Have It?

Use medfinder — we'll call pharmacies near you to find which ones can fill your prescription.

Try hospital-affiliated pharmacies and independent pharmacies, which are more likely to stock low-volume specialty medications.

Ask your pharmacy to order it — most wholesalers can deliver within 1-2 business days.

Talk to your OB/GYN about switching to misoprostol if Methylergonovine is unavailable. Misoprostol is widely available and often costs under $5 with a coupon.

The Outlook for 2026 and Beyond

The FDA's March 2026 ruling enabling new generic injectable manufacturers is a positive development that could gradually improve supply of the injectable form. For oral tablets, supply is expected to remain inconsistent as long as only a small number of manufacturers produce it. Patients should continue to proactively verify availability before their prescription is needed.